Eli Lilly and Company $LLY Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 47.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,309,006 shares of the company’s stock after purchasing an additional 744,868 shares during the period. Eli Lilly and Company accounts for approximately 1.1% of Victory Capital Management Inc.’s investment portfolio, making the stock its 7th biggest position. Victory Capital Management Inc.’s holdings in Eli Lilly and Company were worth $1,761,772,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Sumitomo Mitsui Financial Group Inc. acquired a new stake in Eli Lilly and Company during the second quarter worth approximately $27,000. Evolution Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $29,000. Steph & Co. boosted its stake in Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the period. Financial Gravity Companies Inc. bought a new stake in Eli Lilly and Company in the 2nd quarter valued at $31,000. Finally, Bare Financial Services Inc grew its holdings in Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Orforglipron launch on deck — CFO said Lilly is preparing to launch its oral obesity drug in the U.S. as early as Q2 pending FDA approval, which would be a major new revenue stream if cleared. Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
• Positive Sentiment: Regulatory win in EU — CHMP backed expanded use of Olumiant for adolescents with severe alopecia areata, increasing near‑term sales opportunities in immunology while an EU decision is expected soon. LLY Wins CHMP Nod for Olumiant’s Expanded Use in Alopecia Areata
• Positive Sentiment: Institutional buying noted — filings and commentary suggest smart‑money accumulation during a recent pullback, which can support the stock if momentum re‑accelerates. What Smart Money Loves About Lilly
• Neutral Sentiment: Industry backdrop — Zacks and other analysts flag large‑cap pharma recovery and keep Lilly on watch as part of sector rebound, a contextual tailwind but not an immediate catalyst. Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
• Neutral Sentiment: Investor meetings and presentations — Lilly’s TD Cowen conference presentation (transcript) provides management color on pipeline and commercialization plans; useful for modeling but not a headline surprise. Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Analyst consensus remains constructive — coverage shows an average “Moderate Buy,” offering support but also reflecting already elevated expectations. Eli Lilly and Company (NYSE:LLY) Receives Average Recommendation of “Moderate Buy” from Analysts
• Negative Sentiment: Valuation and momentum cooling — multiple writeups note recent short‑term negative returns and that shares trade at elevated multiples after a multi‑year run, increasing sensitivity to any misses or slower growth. Eli Lilly (LLY) Valuation Check As Momentum Cools After Strong Multi Year Run
• Negative Sentiment: Competition and capacity — Novo Nordisk’s sizable Ireland capacity expansion is a strategic move to defend share in obesity/oral drug markets, posing competitive pressure on Lilly’s launch and pricing dynamics. Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on LLY shares. Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Barclays began coverage on shares of Eli Lilly and Company in a report on Thursday, February 19th. They issued an “overweight” rating and a $1,350.00 price objective for the company. Zacks Research downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Berenberg Bank increased their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research report on Thursday, February 19th. Finally, The Goldman Sachs Group set a $1,260.00 price objective on Eli Lilly and Company in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Stock Down 3.2%

NYSE LLY opened at $1,017.97 on Tuesday. The business has a fifty day moving average price of $1,051.98 and a two-hundred day moving average price of $934.28. The stock has a market capitalization of $960.31 billion, a PE ratio of 44.36, a PEG ratio of 1.22 and a beta of 0.40. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.Eli Lilly and Company’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is presently 30.15%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.